Arvinas, Inc. (ARVN) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello and welcome to the AirVenus 4Q25 earnings call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. And if you would like to withdraw your question, press star one again. Thank you. I will now turn the call over to Jeff Boyle, Head of Impressor Relations. Jeff, you may begin. Good morning, everyone, and thank you for joining us. Earlier today, we issued a press release with our fourth quarter and full year 2025 financial results, which is available in the investor and media section of our website at arvenis.com. Joining us on the call today, we have Randy Teal, our president and CEO, Noah Berkowitz, our chief medical officer, Angela Cacasey, our chief scientific officer, and Andrew Saik, our chief financial officer. Before we begin, I'll remind you that today's discussion contains forward-looking statements that involve risks, uncertainties, and assumptions. These risks and uncertainties are outlined in today's press release and in the company's recent filing with the Securities and Exchange Commission, which I urge you to read. Our actual results may differ materially from what is discussed on today's call. A replay of this call, as well as today's press release and an updated corporate deck, will be available on the Investor and Media section of our website. And now I'll turn the call over to Randy Thiel. Randy? Thanks, Jeff, and thank you all for joining us today. It's an honor and a privilege to lead such a talented and committed team as Arvinas enters a period where we anticipate multiple value driving milestones at the company. In addition to t...